Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Rafferty Asset Management LLC

Rafferty Asset Management LLC lessened its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 18.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 333,391 shares of the biopharmaceutical company's stock after selling 73,883 shares during the quarter. Rafferty Asset Management LLC owned about 0.11% of Amicus Therapeutics worth $3,141,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in FOLD. ProShare Advisors LLC lifted its stake in shares of Amicus Therapeutics by 32.6% in the 4th quarter. ProShare Advisors LLC now owns 96,787 shares of the biopharmaceutical company's stock valued at $912,000 after purchasing an additional 23,815 shares during the last quarter. Prosight Management LP bought a new stake in shares of Amicus Therapeutics in the 4th quarter valued at approximately $8,666,000. Parkman Healthcare Partners LLC lifted its stake in shares of Amicus Therapeutics by 29.6% in the 4th quarter. Parkman Healthcare Partners LLC now owns 784,376 shares of the biopharmaceutical company's stock valued at $7,389,000 after purchasing an additional 179,058 shares during the last quarter. Nuveen Asset Management LLC lifted its stake in shares of Amicus Therapeutics by 4.4% in the 4th quarter. Nuveen Asset Management LLC now owns 3,807,420 shares of the biopharmaceutical company's stock valued at $35,866,000 after purchasing an additional 159,139 shares during the last quarter. Finally, Orbimed Advisors LLC lifted its stake in shares of Amicus Therapeutics by 300.7% in the 4th quarter. Orbimed Advisors LLC now owns 2,285,400 shares of the biopharmaceutical company's stock valued at $21,528,000 after purchasing an additional 1,715,100 shares during the last quarter.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on FOLD shares. UBS Group raised their price objective on Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. The Goldman Sachs Group decreased their price target on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Wall Street Zen lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Finally, Wells Fargo & Company decreased their price target on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research note on Thursday, February 20th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Amicus Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $16.22.

Amicus Therapeutics Trading Down 0.6%

FOLD traded down $0.04 during trading on Friday, hitting $6.22. 2,822,292 shares of the stock were exchanged, compared to its average volume of 2,840,115. The firm has a 50 day simple moving average of $7.11 and a 200 day simple moving average of $8.73. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of -34.56, a P/E/G ratio of 1.51 and a beta of 0.64. Amicus Therapeutics, Inc. has a 1 year low of $5.81 and a 1 year high of $12.65. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.